AR069130A1 - Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento - Google Patents
Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complementoInfo
- Publication number
- AR069130A1 AR069130A1 ARP080104764A ARP080104764A AR069130A1 AR 069130 A1 AR069130 A1 AR 069130A1 AR P080104764 A ARP080104764 A AR P080104764A AR P080104764 A ARP080104764 A AR P080104764A AR 069130 A1 AR069130 A1 AR 069130A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acids
- complement
- modulate
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicacion 2: Una molécula de enlace de C3b aislada, la cual comprende una porcion de enlace de antígeno que se enlaza específicamente con un epítopo de C3b, en donde la porcion de enlace de antígeno se enlaza con un epítopo de C3b humana dentro o traslapándose con uno de los siguientes: (a) aminoácidos GEDTVQSLTQG de la SEQ ID NO:1; (b) aminoácidos DEDIIAEENIVSRSEF de la SEQ ID NO:2; (c) aminoácidos IRMNKTVAVRT de la SEQ ID NO:3; (d) aminoácidos SDQVPDTESET de la SEQ ID NO:4; (4) aminoácidos VAQMTED de la SEQ ID NO:5; (f) aminoácidos FVKRAP de la SEQ ID NO:6; (g) aminoácidos KDKNRWEDPGKQLYN de la SEQ ID NO:7; (h) aminoácidos CTRYRGDQDATMS SEQ ID NO:8; o (i) aminoácidos GFAPDTDDLKQLANGV SEQ ID NO:9. Las moléculas de enlace de C3Bb corresponden a anticuerpos humanos o humanizados. Las composiciones farmacéuticas que comprenden moléculas de enlace de componentes de complemento (ej. C3b) son utiles para tratar la degeneracion macular relacionada con la edad.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98495107P | 2007-11-02 | 2007-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069130A1 true AR069130A1 (es) | 2009-12-30 |
Family
ID=40343498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104764A AR069130A1 (es) | 2007-11-02 | 2008-10-30 | Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20090175875A1 (es) |
| EP (1) | EP2207807A2 (es) |
| JP (1) | JP2011503024A (es) |
| KR (1) | KR20100067681A (es) |
| CN (1) | CN101848937A (es) |
| AR (1) | AR069130A1 (es) |
| AU (1) | AU2008320820A1 (es) |
| CA (1) | CA2703911A1 (es) |
| CL (1) | CL2008003241A1 (es) |
| CO (1) | CO6270341A2 (es) |
| CR (1) | CR11361A (es) |
| EA (1) | EA201000717A1 (es) |
| IL (1) | IL204722A0 (es) |
| MA (1) | MA31795B1 (es) |
| MX (1) | MX2010004833A (es) |
| PE (1) | PE20091388A1 (es) |
| SV (1) | SV2010003556A (es) |
| TN (1) | TN2010000169A1 (es) |
| TW (1) | TW200924795A (es) |
| WO (1) | WO2009056631A2 (es) |
| ZA (1) | ZA201002335B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044111B1 (en) | 2006-06-21 | 2014-08-13 | MUSC Foundation For Research Development | Targeting complement factor h for treatment of diseases |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| EP2222846B1 (en) * | 2007-08-10 | 2017-05-03 | Protelix, Inc. | Universal fibronectin type iii binding-domain libraries |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| JP5698534B2 (ja) | 2007-11-02 | 2015-04-08 | ノバルティス アーゲー | 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用 |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| RS20120461A1 (sr) | 2009-07-02 | 2013-06-28 | Musc Foundation For Research Development | Metode za stimulaciju regeneracije jetre |
| NZ600393A (en) | 2009-11-05 | 2014-08-29 | Alexion Cambridge Corp | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| MX2012013233A (es) | 2010-05-14 | 2013-05-20 | Univ Colorado Regents | Grupos que apuntan a receptor 2 de complemento (cr2) mejorados. |
| CN103249432A (zh) | 2010-06-22 | 2013-08-14 | 科罗拉多大学董事会,法人团体 | 补体成分3的C3d片段的抗体 |
| AU2011336702B2 (en) * | 2010-11-29 | 2016-10-06 | Novelmed Therapeutics, Inc. | Neoantibodies for diagnosing tissue injury |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| KR101834469B1 (ko) | 2013-08-07 | 2018-03-06 | 알렉시온 파마슈티칼스, 인코포레이티드 | 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질 |
| CA2936346A1 (en) | 2014-01-08 | 2015-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody targeting cell surface deposited complement protein c3d and use thereof |
| WO2016033382A1 (en) * | 2014-08-27 | 2016-03-03 | Capnia, Inc. | Methods for immune globulin administration |
| US10640540B2 (en) | 2015-12-23 | 2020-05-05 | Greenovation Biotech Gmbh | Polypeptides for inhibiting complement activation |
| KR102667023B1 (ko) | 2016-06-14 | 2024-05-21 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 및 이의 용도 |
| WO2018075474A1 (en) | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating central nervous system injury |
| CN120571008A (zh) | 2017-12-13 | 2025-09-02 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| CN111171147B (zh) * | 2020-02-11 | 2021-07-20 | 北京康普美特创新医药科技有限责任公司 | 一种抗补体c3分子的全人源单克隆抗体及应用 |
| AU2022420788A1 (en) | 2021-12-22 | 2024-05-16 | Boehringer Ingelheim International Gmbh | Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases |
| AU2023347940A1 (en) * | 2022-09-20 | 2025-03-27 | Visterra, Inc. | Treatment of complement mediated diseases and disorders with c3b-antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| US5932217A (en) * | 1991-05-03 | 1999-08-03 | The Rockefeller University | Peptides which inhibit adhesion between leukocytes and endothelial cells |
| AU6397796A (en) * | 1995-06-29 | 1997-01-30 | Medical Biology Institute | Method for identifying peptides that affect protein-protein interactions and complement-modulating peptides |
| WO2002088750A2 (en) * | 2001-05-02 | 2002-11-07 | Oxford Glycosciences (Uk) Ltd | Proteins, genes and their use for diagnosis and treatment of breast cancer |
| US7042716B2 (en) * | 2003-08-25 | 2006-05-09 | Simon John Edward Shearman | Ergonomic pull-out computer housing |
| WO2006012621A2 (en) * | 2004-07-23 | 2006-02-02 | University Of Virginia Patent Foundation | Compositions and methods for regulating the alternative pathway of complement |
| US7947267B2 (en) * | 2004-10-08 | 2011-05-24 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
| AU2006304605A1 (en) * | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US7327547B1 (en) * | 2006-01-20 | 2008-02-05 | Epstein Barry M | Circuit element and use thereof |
| KR20150029002A (ko) * | 2007-06-07 | 2015-03-17 | 제넨테크, 인크. | 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법 |
-
2008
- 2008-10-30 CL CL2008003241A patent/CL2008003241A1/es unknown
- 2008-10-30 AR ARP080104764A patent/AR069130A1/es unknown
- 2008-10-30 PE PE2008001860A patent/PE20091388A1/es not_active Application Discontinuation
- 2008-10-31 WO PCT/EP2008/064809 patent/WO2009056631A2/en not_active Ceased
- 2008-10-31 EP EP08844727A patent/EP2207807A2/en not_active Withdrawn
- 2008-10-31 EA EA201000717A patent/EA201000717A1/ru unknown
- 2008-10-31 KR KR1020107009602A patent/KR20100067681A/ko not_active Ceased
- 2008-10-31 JP JP2010532555A patent/JP2011503024A/ja active Pending
- 2008-10-31 TW TW097142274A patent/TW200924795A/zh unknown
- 2008-10-31 CN CN200880114277A patent/CN101848937A/zh active Pending
- 2008-10-31 CA CA2703911A patent/CA2703911A1/en not_active Abandoned
- 2008-10-31 AU AU2008320820A patent/AU2008320820A1/en not_active Abandoned
- 2008-10-31 MX MX2010004833A patent/MX2010004833A/es not_active Application Discontinuation
- 2008-11-03 US US12/263,909 patent/US20090175875A1/en not_active Abandoned
-
2010
- 2010-03-25 IL IL204722A patent/IL204722A0/en unknown
- 2010-04-01 ZA ZA2010/02335A patent/ZA201002335B/en unknown
- 2010-04-09 CR CR11361A patent/CR11361A/es not_active Application Discontinuation
- 2010-04-16 TN TN2010000169A patent/TN2010000169A1/fr unknown
- 2010-04-28 CO CO10050312A patent/CO6270341A2/es not_active Application Discontinuation
- 2010-04-30 SV SV2010003556A patent/SV2010003556A/es not_active Application Discontinuation
- 2010-04-30 MA MA32801A patent/MA31795B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6270341A2 (es) | 2011-04-20 |
| CR11361A (es) | 2010-06-01 |
| IL204722A0 (en) | 2010-11-30 |
| PE20091388A1 (es) | 2009-09-24 |
| JP2011503024A (ja) | 2011-01-27 |
| CA2703911A1 (en) | 2009-05-07 |
| MX2010004833A (es) | 2010-05-27 |
| TN2010000169A1 (en) | 2011-11-11 |
| SV2010003556A (es) | 2011-03-23 |
| WO2009056631A3 (en) | 2009-08-20 |
| US20090175875A1 (en) | 2009-07-09 |
| EP2207807A2 (en) | 2010-07-21 |
| ZA201002335B (en) | 2011-02-23 |
| WO2009056631A2 (en) | 2009-05-07 |
| CN101848937A (zh) | 2010-09-29 |
| AU2008320820A1 (en) | 2009-05-07 |
| MA31795B1 (fr) | 2010-10-01 |
| TW200924795A (en) | 2009-06-16 |
| CL2008003241A1 (es) | 2009-07-31 |
| EA201000717A1 (ru) | 2010-12-30 |
| KR20100067681A (ko) | 2010-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069130A1 (es) | Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento | |
| ES2689080T3 (es) | Anticuerpos que se unen a TL1A y sus usos | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20090831A1 (es) | Anticuerpo monoclonal | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
| PE20081478A1 (es) | Anticuerpos cd44 | |
| AR062895A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
| PE20091382A1 (es) | Anticuerpos que se une a il-4 y/o a il-13 | |
| BR112014001573B8 (pt) | Molécula fv ao antígeno multivalente | |
| BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
| CO6331370A2 (es) | Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos | |
| PE20120343A1 (es) | Anticuerpo anti-cmet que comprende una region bisagra | |
| AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| CL2018001238A1 (es) | Moléculas de unión específicas para asct2 y usos de las mismas | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| PE20180502A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
| MX2009009636A (es) | Metodos para tratar enfermedades oftalmicas. | |
| AR066170A1 (es) | Anti integrina alfa 5 beta 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |